Case reports suggest a broader range of sexual adverse events in patients receiving finasteride [Propecia, Proscar] than previously reported,

Excerpt

Case reports suggest a broader range of sexual adverse events in patients receiving finasteride [Propecia, Proscar] than previously reported, says the US FDA. The labels for Propecia and Proscar will be revised to offer an expanded list of events, including libido disorders, ejaculation disorders and orgasm disorders that have been reported to have continued after discontinuation of the drug, as well as reports of male infertility and/or poor semen quality that normalised or improved after drug discontinuation. The FDA states, however, that clear causal links between finasteride use and sexual adverse events have not yet been established. …